Loading…
Chinese biotech developing plant-based (rice) recombinant human serum albumin and other recombinant proteins.
Chinese biotech developing plant-based (rice) recombinant human serum albumin and other recombinant proteins.
In one line: A niche plant-made-biologics company.
Moat: narrow (IP / patents, process know-how). Proprietary rice-seed bioreactor platform for producing recombinant albumin, a novel manufacturing route.
Headquarters: Wuhan, China · Employees: 253
Size Wuhan Healthgen Biotechnology (688765.SS) is a China Health Care company (Biotechnology) with a market value of $1.64B, the 1505th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥31.11 on 6 Nov 2026.
Performance Over six months the shares fell 43.5%, against -8.7% for the median peer and -16.4% for the China market (cap-weighted) — 2nd lowest of 18 in its peer set.
Growth Revenue grew 89.8% over the last twelve months (peer median +21.1%); the operating margin is -297.1% (peer median -4.9%).
Valuation It trades at 231.2× enterprise value to sales against a peer median of 11.8× (3rd most expensive of 17).
Capital Return on invested capital runs 15.4 points below its cost of capital (11.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | CN¥47.9M | CN¥25.2M | CN¥22.4M | CN¥12.6M |
| Revenue growth | — | +90% | +12% | +78% | — |
| Gross profit | n/a | -CN¥33.2M | -CN¥38.3M | -CN¥28.3M | -CN¥2.55M |
| EBITDA | n/a | -CN¥75.9M | -CN¥105M | -CN¥160M | -CN¥150M |
| Net income | n/a | -CN¥157M | -CN¥151M | -CN¥187M | -CN¥144M |
| Free cash flow | n/a | -CN¥666M | -CN¥220M | -CN¥224M | -CN¥425M |
| Capital expenditure | n/a | CN¥538M | CN¥167M | CN¥102M | CN¥358M |
| Total debt | CN¥369M | CN¥368M | CN¥223M | CN¥93.9M | CN¥15.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Wuhan Healthgen Biotechnology 688765.SS | $1.64B | -44% | +90% | -297% | 231.2× | n/a |
| Shanghai RAAS Blood Products 002252.SZ | $4.89B | -11% | -22% | 17% | 5.7× | n/a |
| Hualan Biological Engineering 002007.SZ | $3.37B | -15% | -11% | 17% | 5.6× | 16.7% |
| CSL CSL.AX | $67.2B | +105% | -2% | 26% | 4.9× | 7.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688765.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.1% | -8.8% | 9th lowest of 20 |
| 6-month return | -43.5% | -8.7% | 2nd lowest of 18 |
| Distance from 52-week high | -76.4% | -39.2% | lowest of 20 |
| Revenue growth (TTM) | +89.8% | +21.1% | 4th highest of 19 |
| Operating margin | -297.1% | -4.9% | 8th lowest of 19 |
| EV / Sales | 231.2× | 11.8× | 3rd most expensive of 17 |
| ROIC minus cost of capital | -15.4 pp | -6.8 pp | 6th lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | 231.2× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | 369.5× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | 1.0× | -19.0% | +36.4% |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | 40.2× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.71B | -5% | +36% | -4% | 8.7× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | 14.8× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.72B | +45% | +16% | -5% | 6.2× | 45.1% | -2.5% |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.74B | -19% | -86% | -913% | 50.3× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| Absci ABSI | United States | $1.75B | +72% | -62% | -8,411% | 991.7× | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.76B | n/a | -55% | -593% | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.76B | -23% | +71% | 0% | 4.5× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | n/a | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 4.4× | -7.9% | +15.0% |